Celgene Corporation (NASDAQ:CELG) Director Michael D. Casey sold 9,250 shares of Celgene Corporation stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $139.03, for a total transaction of $1,286,027.50. Following the completion of the sale, the director now owns 9,250 shares in the company, valued at $1,286,027.50. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Michael D. Casey also recently made the following trade(s):

  • On Monday, June 19th, Michael D. Casey sold 9,250 shares of Celgene Corporation stock. The shares were sold at an average price of $125.59, for a total transaction of $1,161,707.50.

Shares of Celgene Corporation (NASDAQ CELG) opened at 140.50 on Friday. Celgene Corporation has a one year low of $96.93 and a one year high of $142.64. The stock’s 50 day moving average is $134.31 and its 200-day moving average is $126.68. The company has a market cap of $109.92 billion, a P/E ratio of 43.51 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, beating the consensus estimate of $1.61 by $0.21. The company had revenue of $3.27 billion during the quarter, compared to analysts’ expectations of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. Celgene Corporation’s revenue for the quarter was up 18.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.44 earnings per share. Equities research analysts forecast that Celgene Corporation will post $7.32 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Celgene Corporation (CELG) Director Sells $1,286,027.50 in Stock” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.thecerbatgem.com/2017/09/09/celgene-corporation-celg-director-sells-1286027-50-in-stock.html.

Several equities research analysts have issued reports on CELG shares. Jefferies Group LLC set a $154.00 price target on shares of Celgene Corporation and gave the company a “buy” rating in a research note on Saturday, May 13th. Goldman Sachs Group, Inc. (The) reiterated a “sell” rating and issued a $98.00 price target (up from $93.00) on shares of Celgene Corporation in a research note on Wednesday, May 17th. Vetr upgraded shares of Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $134.80 price target on the stock in a research note on Wednesday, May 17th. Robert W. Baird reiterated an “outperform” rating and issued a $162.00 price target on shares of Celgene Corporation in a research note on Monday, May 22nd. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $152.00 price target on shares of Celgene Corporation in a research note on Tuesday, May 23rd. One research analyst has rated the stock with a sell rating, seven have given a hold rating and twenty-two have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $147.31.

Large investors have recently modified their holdings of the stock. Lincoln Capital Corp grew its stake in Celgene Corporation by 0.6% during the second quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock valued at $3,971,000 after acquiring an additional 185 shares in the last quarter. Swiss National Bank grew its stake in Celgene Corporation by 27.2% during the first quarter. Swiss National Bank now owns 2,746,896 shares of the biopharmaceutical company’s stock valued at $341,796,000 after acquiring an additional 588,000 shares in the last quarter. Boston Partners grew its stake in Celgene Corporation by 0.3% during the first quarter. Boston Partners now owns 197,861 shares of the biopharmaceutical company’s stock valued at $24,620,000 after acquiring an additional 541 shares in the last quarter. Russell Investments Group Ltd. grew its stake in Celgene Corporation by 9.2% during the second quarter. Russell Investments Group Ltd. now owns 641,697 shares of the biopharmaceutical company’s stock valued at $83,344,000 after acquiring an additional 54,210 shares in the last quarter. Finally, Chicago Equity Partners LLC grew its stake in Celgene Corporation by 148.8% during the first quarter. Chicago Equity Partners LLC now owns 86,480 shares of the biopharmaceutical company’s stock valued at $10,761,000 after acquiring an additional 51,715 shares in the last quarter. 79.43% of the stock is owned by institutional investors.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Insider Buying and Selling by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.